Novartis looks set to gain the first ever radiopharmaceutical approval in a frontline setting after Lutathera achieved success in a Phase III study in pancreatic cancer.
The Swiss pharma giant has reported that the NETTER-2 trial met its primary endpoint of improvement in progression-free survival (PFS)...
Welcome to Scrip
Create an account to read this article
Already a subscriber?